公开(公告)号：US12129242B2

公开(公告)日：2024-10-29

申请号：US17709242

申请日：2022-03-30

申请人： NATIONAL TAIWAN UNIVERSITY ,  NATIONAL YANG MING CHIAO TUNG UNIVERSITY ,  NATIONAL HEALTH RESEARCH INSTITUTES ,  Yufeng Jane Tseng

发明人： Yufeng Jane Tseng ,  Yu-Li Liu ,  Chung-Ming Sun ,  Wen-Sung Lai ,  Chih-Min Liu ,  Hai-Gwo Hwu

IPC分类号： C07D401/12 ,  A61P25/18 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14

CPC分类号： C07D401/12 ,  A61P25/18 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14

摘要： The present invention provides novel substituted benzimidazole derivatives used as DAAO inhibitors and for treatment and/or prevention of neurological disorders.

公开(公告)号：US20240350453A1

公开(公告)日：2024-10-24

申请号：US18429524

申请日：2024-02-01

申请人： Sumitomo Pharma America, Inc.

发明人： Seth Cabot HOPKINS

IPC分类号： A61K31/381 ,  A61P25/18

CPC分类号： A61K31/381 ,  A61P25/18

摘要： The present disclosure relates to methods of treating neurological or psychiatric diseases or disorders, such as schizophrenia. Compound 1, or a pharmaceutically acceptable salt thereof, is an antipsychotic agent with a non-D2 mechanism of action. Adverse events associated with antipsychotic agents that target the D2 dopamine receptor can be reduced by treating disorders with Compound 1, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US12121609B2

公开(公告)日：2024-10-22

申请号：US17079498

申请日：2020-10-25

申请人： Biohaven Therapeutics Ltd.

发明人： Vladimir Coric ,  Robert Berman ,  Ronald S. Vladyka ,  Amgad Saleh ,  Danny Yu

IPC分类号： A61K31/428 ,  A61K9/00 ,  A61K9/08 ,  A61K9/20 ,  A61K47/20 ,  A61K47/26 ,  A61P25/00 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30

CPC分类号： A61K9/006 ,  A61K9/0056 ,  A61K9/08 ,  A61K9/20 ,  A61K31/428 ,  A61K47/20 ,  A61K47/26 ,  A61P25/00 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30

摘要： Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided. In addition, a method of relieving or reducing oral pain using the sublingual formulation of riluzole is disclosed.

公开(公告)号：US20240335426A1

公开(公告)日：2024-10-10

申请号：US18748709

申请日：2024-06-20

申请人： Boehringer Ingelheim International GmbH

发明人： Jana PODHORNA ,  Holger ROSENBROCK ,  Sun Young YUM ,  Yihua ZHAO

IPC分类号： A61K31/422 ,  A61P25/18 ,  A61P25/28

CPC分类号： A61K31/422 ,  A61P25/18 ,  A61P25/28

摘要： The invention relates to the treatment of cognitive impairment associated with schizophrenia (CIAS) with a specific GlyT1 inhibitor ([5-(methylsulfonyl)-2-{[(2R)-1,1,1-trifluoropropan-2-yl]oxy}phenyl]{(1R,5R)-1-[5-(trifluoromethyl)-1,2-oxazol-3-yl]-3-azabicyclo[3.1.0]hex-3-yl}methanone). A 12-week treatment in a phase 2 study showed improvement in cognitive function as measured by the MATRICS Consensus Cognitive Battery (MCCB) overall composite score.

公开(公告)号：US20240325293A1

公开(公告)日：2024-10-03

申请号：US18585349

申请日：2024-02-23

申请人： MedinCell S.A.

发明人： Avia Merenlender Wagner ,  Anna Elgart VALITSKY ,  Eran Harary

IPC分类号： A61K9/00 ,  A61K31/519 ,  A61K47/10 ,  A61K47/34 ,  A61P25/18

CPC分类号： A61K9/0019 ,  A61K31/519 ,  A61K47/10 ,  A61K47/34 ,  A61P25/18

摘要： The present invention is directed to methods of treating psychiatric diseases and disorders comprising administering to a subject in need thereof at a frequency of no more than once every 28 days an injectable formulation comprising risperidone, triblock and diblock copolymers wherein the concentration of the risperidone is 250-400 mg/mL and injection volume is 1 mL or less.

公开(公告)号：US20240299393A1

公开(公告)日：2024-09-12

申请号：US18570787

申请日：2022-06-17

申请人： Dana-Farber Cancer Institute, Inc. ,  University of Liege

发明人： Julien Olivet ,  Soon Gang Choi ,  Jean-Claude Twizere ,  Marc Vidal ,  Sara Buhrlage

IPC分类号： A61K31/519 ,  A61P25/18 ,  A61P35/00

CPC分类号： A61K31/519 ,  A61P25/18 ,  A61P35/00

摘要： Disclosed are compounds, compositions, and methods useful for disrupting protein interactions in a histone deacetylase (HDAC) complex in a cell of subject or for treating a disease mediated by a histone deacetylase (HDAC) complex in a subject.

公开(公告)号：US20240252471A1

公开(公告)日：2024-08-01

申请号：US18526686

申请日：2023-12-01

申请人： BioXcel Therapeutics, Inc.

发明人： Vasukumar KAKUMANU ,  David Christian HANLEY ,  Frank YOCCA ,  Chetan Dalpatbhai LATHIA ,  Lavanya RAJACHANDRAN ,  Robert RISINGER

IPC分类号： A61K31/4174 ,  A61K9/00 ,  A61K47/38 ,  A61P25/18 ,  A61P25/20

CPC分类号： A61K31/4174 ,  A61K9/006 ,  A61K47/38 ,  A61P25/18 ,  A61P25/20

摘要： Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.

公开(公告)号：US20240246912A1

公开(公告)日：2024-07-25

申请号：US18591925

申请日：2024-02-29

申请人： Canna-Chemistries LLC

发明人： Nate Schultheiss ,  Travis Lee Houston ,  Stephan D. Parent

IPC分类号： C07D209/16 ,  A61P25/18

CPC分类号： C07D209/16 ,  A61P25/18 ,  C07B2200/13

摘要： Crystalline salts of psilocin are disclosed. The beneficial and therapeutic uses of the crystalline psilocin salts and of compositions containing the crystalline psilocin salts are also disclosed. The disclosure sets out methods of making and characterizing the crystalline psilocin salts.

公开(公告)号：US12029712B2

公开(公告)日：2024-07-09

申请号：US16884652

申请日：2020-05-27

申请人： Sun Pharmaceutical Industries, Inc.

发明人： Dario Doller ,  Christopher L. Brummel ,  Julie F. Liu ,  Roger D. Tung

IPC分类号： A61K31/197 ,  A61K9/00 ,  A61K31/198 ,  A61K45/06 ,  A61P25/18

CPC分类号： A61K31/197 ,  A61K9/0053 ,  A61K31/198 ,  A61K45/06 ,  A61P25/18

摘要： This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.

公开(公告)号：US20240208988A1

公开(公告)日：2024-06-27

申请号：US18562605

申请日：2022-06-14

申请人： NAPO PHARMACEUTICALS, INC.

发明人： Steven King ,  Karen Brunke ,  Elaine Elisabetsky ,  Maurice M. Iwu

IPC分类号： C07D491/22 ,  A61K31/4375 ,  A61K45/06 ,  A61P25/18

CPC分类号： C07D491/22 ,  A61K31/4375 ,  A61K45/06 ,  A61P25/18

摘要： The present disclosure is concerned with alstonine, alstonine analogs, and salts thereof for the treatment of various disorders where changes in 5-HT2A/5-HT2C receptor signaling and/or dopamine transporter activity may be beneficial such as, for example, psychotic disorders, epilepsy, and anxiety disorders. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.